Table 3.
Cox Regression Analysis for Adverse Outcomes Between LARR and No LARR Groups Among HFrecEF Subtype
| Clinical outcomes | Unadjusted | Fully adjusted * | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P value | |
| Cardiovascular death or heart failure hospitalization | … | … | … | … | … | … |
| No LARR vs LARR | 2.276 | 1.149–4.509 | 0.018 | 2.745 | 1.348–5.589 | 0.005 |
| Cardiovascular death | … | … | … | … | … | … |
| No LARR vs LARR | 3.809 | 1.194–12.150 | 0.024 | 3.613 | 1.088–11.992 | 0.036 |
| Heart failure hospitalization | … | … | … | … | … | … |
| No LARR vs LARR | 1.700 | 0.722–4.005 | 0.225 | 2.101 | 0.870–5.072 | 0.099 |
HR indicates hazard ratio; and LARR, left atrial reverse remodeling.
*
Adjusted for age, sex, B‐type natriuretic peptide, and left ventricular ejection fraction.